thrombocytopenic purpura
Recently Published Documents


TOTAL DOCUMENTS

8725
(FIVE YEARS 1050)

H-INDEX

133
(FIVE YEARS 9)

Medicine ◽  
2022 ◽  
Vol 101 (2) ◽  
pp. e28417
Author(s):  
Naidan Zhang ◽  
Chaixia Ji ◽  
Xiao Bao ◽  
Chengliang Yuan

Author(s):  
Lucas Kühne ◽  
Jessica Kaufeld ◽  
Linus A. Völker ◽  
Ralph Wendt ◽  
Ulf Schönermarck ◽  
...  

2022 ◽  
Vol 54 (4) ◽  
pp. 373-376
Author(s):  
Samar Iltaf ◽  
Saira Awan ◽  
Saira Abbas ◽  
Salma Salman ◽  
Shariq Mirza

Cannabis used as both for medicine as well as recreational purposes. Extensive use is associated with many documented central nervous system and hepatic manifestation. How-ever only few cases are reported in literature with cardiac and hematological manifestation. Our case report is one of its kinds where our patient presents with thrombotic thrombocytopenic purpura and atrial fibrillation and he required extensive treatment including plasmapharesis.


Life ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 80
Author(s):  
Cristina-Florentina Plesa ◽  
Diana Maria Chitimus ◽  
Carmen Adella Sirbu ◽  
Monica Marilena Țânțu ◽  
Minerva Claudia Ghinescu ◽  
...  

Background: Secondary thrombotic thrombocytopenic purpura (TTP) due to interferon beta-1a intramuscular (im) treatment is an uncommon adverse effect with only a few cases in multiple sclerosis patients reported worldwide. TTP together with haemolytic uremic syndrome (HUS) are classic forms of thrombotic microangiopathy, characterized by small-vessel platelet micro-thrombi that manifest clinically in a similar manner. Most common signs and symptoms include bruises and ecchymosis, neurologic symptoms and renal impairment. Interferon beta-1a represents one of the first-line therapies for relapsing-remitting multiple sclerosis due to its accessibility and efficacy. Case presentation: A 36-year-old woman who was previously diagnosed with relapsing-remitting multiple sclerosis had received weekly intramuscular injections with beta-interferon-1a (Avonex 30 mcg). After 9 months of treatment, she presented bruises and ecchymosis on her limbs and torso, epistaxis, gingival bleeding aggravated within 48 h and a persistent headache that was non-responsive to common analgesics. Haematology tests revealed typical results for thrombotic microangiopathy, including severe thrombocytopenia (4000/mm3) and microangiopathic haemolytic anaemia with frequent schistocytes on the peripheral blood smear. Once the beta-interferon administration was ceased and upon the initiation of methylprednisolone, the symptoms remitted. Conclusions: In this case study, we portrayed the particular association between the remission phase of multiple sclerosis and the violent onset of interferon-induced thrombotic thrombocytopenic purpura.


2022 ◽  
Vol 71 (12) ◽  
Author(s):  
Pooja Deepak ◽  
Roha Saeed Memon ◽  
Fizza Tariq ◽  
Hassan Ahmed ◽  
Shaheen Bhatti

Systemic lupus erythematosus (SLE) is an autoimmune disease that has certain characteristic features but can also present with misleading signs and symptoms especially when it is of late-onset. Various case reports address its association with thrombotic thrombocytopenic purpura (TTP), however, its association with parkinsonism remains unclear. We present the case of a 58-year-old male who reported with acute-onset parkinsonism along with some gastrointestinal symptoms. Detailed laboratory investigations unmasked the underlying SLE with an overlapping picture of TTP. This unusual presentation in a resource-constrained setting created challenges and subsequent delays in the diagnosis and management of the patient. Despite urgent care, the patient’s age, presence of overlapping conditions, and multi-organ involvement were some of the factors due to which the treatment failed and he could not survive. We report the association of SLE with secondary TTP and parkinsonism.


Author(s):  
Kikuaki Yoshida ◽  
Ayaka Sakaki ◽  
Yoriko Matsuyama ◽  
Toshiki Mushino ◽  
Masanori Matsumoto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document